Results 231 to 240 of about 52,862 (295)

Geranylgeraniol as a Modulator of Mevalonate Pathway Disruption: A Scoping Review of Cellular Mechanisms and Skeletal Outcomes in Osteoporosis Models. [PDF]

Pharmaceuticals (Basel)
Ekeuku SO, Al Salman MFA, Mohamad NV, Wong SK, Chin KY.   +4 more
europepmc   +1 more source

Bone health in advanced prostate cancer: pathophysiology and management strategies. [PDF]

Oncologist
McKay RR, Hofflich H, Woods G, Andres R, Farooki A.   +4 more
europepmc   +1 more source

Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper

International Journal of Gynecology &Obstetrics, Volume 175, Issue 1, Page 26-47, October 2026.
Abstract Premature ovarian insufficiency (POI) and early menopause (EM) affect millions of women worldwide. Compared with normal menopause, they confer a longer duration of estrogen deficiency and are associated not only with a shorter lifespan, but with a reduced healthspan, owing to an increased risk of cardiovascular, skeletal, cognitive and ...
Chiara Benedetto, Suvarna S. Khadilkar, Rossella E. Nappi, Andrea R. Genazzani, Federica Frezet, Laura Cucinella, Hema Divakar, Panagiotis Anagnostis, Nick Panay   +8 more
wiley   +1 more source

Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of medication-related osteonecrosis of the jaw: a retrospective longitudinal cohort study. [PDF]

Dentomaxillofac Radiol
Radi S, El Bachaoui S, Tsiklin I, Pastenes C, De Backer H, Coropciuc R, Van den Wyngaert T, Beuselinck B, Jacobs R.   +8 more
europepmc   +1 more source

Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3‐Year Prospective Study

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 5, October 2026.
ABSTRACT Background Osteoporosis and sarcopenia frequently coexist in older adults, yet whether denosumab provides muscle‐related benefits beyond bone remains uncertain. We compared denosumab and zoledronic acid across functional, imaging, biologic and study‐defined sarcopenia outcomes based on an Asian Working Group for Sarcopenia (AWGS) 2025‐informed
Xiangwen Li, Zineng Yuan, Nina Ma, Bijuan Huang, Hongyue Tao, Shuang Chen   +5 more
wiley   +1 more source

Fragility fracture, atypical femoral fracture, and osteonecrosis of jaw after bisphosphonate prescription for three and five years, based on primary and secondary care data in England: nested case-control and cohort studies. [PDF]

BMJ Med
Nakafero G, McKeever T, Kukreja NS, Welsh V, Muller S, Abhishek A.   +5 more
europepmc   +1 more source

Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.
ABSTRACT Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa).
Emanuela Gentile, Paul G. Corn, Martha Zavridou, James P. Long, Jian H. Song, Anh Hoang, Andrew W. Hahn, Eleonora Dondossola, William Norton, Sue‐Hwa Lin, Christopher J. Logothetis, Theocharis Panaretakis   +11 more
wiley   +1 more source

Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis: A GRADE-assessed systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Shah A, Khan S, Rizvi SVZ, Farhan K, Uddin M, Rizvi SUA, Fatima S, Karan AR, Khalid AA, Ali A, Ahmed S.   +10 more
europepmc   +1 more source

The Bisphosphonate Accumulation Index (BAI): A Quantitative Metric for Cumulative Antiresorptive Exposure in Pre-Procedural Dental and Surgical Assessment. [PDF]

Dent J (Basel)
Zecca PA, Miotto RE, Brusamolino F, Vercellini N, Serafin M, Borgese M.   +5 more
europepmc   +1 more source